Ofer Shpilberg

39 Zabotinski St
Petah Tiqwa, M 49100, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 107 publications

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Journal: Lancet (London, England)

Published: December 23, 2025

Epigenetic dysregulation in Erdheim-Chester disease: perspectives from tissue and blood.

Epigenetic dysregulation in Erdheim-Chester disease: perspectives from tissue and blood.

Journal: Leukemia

Published: August 26, 2025

Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.

Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.

Journal: Haematologica

Published: August 12, 2025

EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.

EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.

Journal: HemaSphere

Published: June 30, 2025

Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.

Loss of miR-146a-5p contributes to ibrutinib resistance in mantle cell lymphoma.

Journal: Blood advances

Published: March 28, 2025

The molecular landscape of AL amyloidosis.

The molecular landscape of AL amyloidosis.

Journal: British journal of haematology

Published: January 24, 2025

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.

Journal: Cancer cell

Published: November 22, 2024

The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms.

The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms.

Journal: Leukemia

Published: September 07, 2024

Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia.

Novel dual action chimera doxorubizen demonstrates superior efficacy to doxorubicin in acute leukemia.

Journal: Scientific reports

Published: September 05, 2024

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.

Journal: British journal of haematology

Published: February 05, 2024

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.

Journal: Lancet (London, England)

Published: September 01, 2023

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.

Journal: HemaSphere

Published: December 08, 2022

Showing 1-12 of 107

Last Updated: 09/26/2026